P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Liminal BioSciences news
11.05.2022
Liminal BioSciences reported an IFRS loss of C$11.164 million for the 3 months of 2022, down 46.5% from C$20.849 million in the previous year. The company did not generate revenue. A year earlier the figure was C$210 thousand.
Source: app.quotemedia.com
18.03.2022
Liminal BioSciences' IFRS net income for 2021 was C$12.213 million, compared to a loss of C$118.757 million in the previous year. Revenue decreased 11.2% to C$643,000 from C$724,000 a year earlier.
Source: app.quotemedia.com
18.11.2021
Liminal BioSciences' IFRS net income for 9M 2021 was $29.278 mln, compared to a loss of $78.766 mln in the previous year. Revenues decreased 8% to $405,000 from $440,000 a year earlier.
Source: content.cdntwrk.com
17.08.2021
Liminal BioSciences' IFRS loss for 6M 2021 was $52.982 million, down 4.5% from $55.473 million in the previous year. Revenue decreased 1.3% to $235,000 from $238,000 a year earlier.
Source: dd7pmep5szm19.cloudfront.net
General information
| Company name | Liminal BioSciences |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 440 Armand-Frappier Boulevard Suite 300 Laval, QC H7V 4B4 Canada |
| Mailing address | 440 Armand-Frappier Boulevard Suite 300 Laval, QC H7V 4B4 Canada |
| Website | liminalbiosciences.com |
| Information disclosure | www.sec.gov |
English (US) 